UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 19, 2026
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-39231
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
Address Not Applicable1
|
|
ZIP Code Not Applicable
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(267) 866‑0311
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| ☐ |
Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12)
|
| ☐ |
Pre‑commencement communications pursuant to Rule 14d‑2(b) under the Exchange Act (17 CFR 240.14d‑2(b))
|
| ☐ |
Pre‑commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
Common Stock, $0.0001 par value per share
|
|
|
|
The Nasdaq Stock Market LLC
(Nasdaq Capital Market)
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b‑2
of the Securities Exchange Act of 1934 (§240.12b‑2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1 We are a remote-only
company. Accordingly, we do not maintain a headquarters. For purposes of compliance with
applicable requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, any stockholder communication required to be sent to our principal executive offices may be directed to P.O. Box 7, Hopewell,
New Jersey 08525.
As previously disclosed, on November 5, 2026, Passage Bio, Inc. (“Passage Bio”)
held a Special Meeting of Stockholders (the “Special Meeting”). At the Special Meeting, Passage Bio’s stockholders considered and approved proposals which
related to the Amended and Restated Agreement and Plan of Merger by and among Passage Bio, Peregrine Merger Sub, Inc., Peregrine Merger Sub II, LLC, and Remix Therapeutics, Inc. (“Remix”), dated as of September 2, 2026, and further amended on October 5, 2026 (the “Merger Agreement”), pursuant to which,
among other matters, Peregrine Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Passage Bio (“Merger Sub”), will merge with and into
Remix, with Remix surviving as a wholly owned subsidiary of Passage Bio (the “First Merger”), and immediately following thereof, Remix will merge with and
into Peregrine Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Passage Bio (“Merger Sub II”), with Merger Sub II
surviving as a wholly owned subsidiary of Passage Bio ( the “Second Merger” and, together with the First Merger, the “Mergers”).
Passage Bio is filing this Current Report on Form 8-K to provide certain financial information with respect to the proposed Mergers. Specifically, this Current Report on
Form 8-K provides: (1) the unaudited condensed interim financial statements of Remix as of and for the nine months ended September 30, 2026 and 2025, attached hereto as Exhibit 99.1 and incorporated herein by reference, and (2) the unaudited pro
forma combined condensed financial information of Passage Bio, Remix, and the combined company resulting from the Mergers, as of and for the nine months ended September 30, 2026 and the year ended December 31, 2025, relating to the proposed
Mergers, attached hereto as Exhibit 99.2 and incorporated herein by reference. Such unaudited pro forma condensed financial statements have been prepared on the basis of certain assumptions and estimates and are subject to other uncertainties and
do not purport to reflect what the actual results of operations or financial condition of the combined company would have been had the Mergers been consummated on the dates assumed for purposes of such pro forma financial statements or to be
indicative of the financial condition or results of operations of the combined company as of or for any future date or period. For further information, see Exhibit 99.2. The information in Exhibit 99.1 was provided by Remix.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(a) Financial Statements of Businesses to be Acquired.
The unaudited condensed interim financial statements of Remix as of September 30, 2026 and for the nine month periods ended September 30, 2026 and 2025 are filed herewith
as Exhibit 99.1 and incorporated in this Item 9.01(a) by reference.
(b) Pro Forma Financial Information.
The unaudited pro forma combined condensed financial information of Passage Bio, Remix, and the combined company resulting from the Mergers as of and for the nine months
ended September 30, 2026 and the year ended December 31, 2025, relating to the proposed Mergers, are filed herewith as Exhibit 99.2 and incorporated in this Item 9.01(b) by reference.
(d) Exhibits
|
Exhibit No.
|
Description
|
|
|
Unaudited Condensed Interim Financial Statements of Remix Therapeutics, Inc. as of and for the nine months ended September 30, 2026 and 2025.
|
|
|
Unaudited Pro Forma Combined Condensed Financial Information of Passage Bio, Inc., Remix Therapeutics, Inc., and the combined company resulting from the Mergers as of and for the
nine months ended September 30, 2026, and the year ended December 31, 2025.
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements
regarding the current expectations and projections of the financial statements of the combined company resulting from the Mergers and the proposed transaction involving Passage Bio and Remix, among others. Forward-looking statements generally
include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,”
“intend,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and
are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: (i) the risk that the conditions to the closing of
the proposed transaction are not satisfied, including the failure to timely or at all obtain any required regulatory clearances; (ii) uncertainties as to the timing of the consummation of the proposed transaction and the ability of each of Passage
Bio and Remix to consummate the proposed transaction; (iii) the ability of Passage Bio and Remix to integrate their businesses successfully and to achieve anticipated synergies; (iv) the possibility that other anticipated benefits of the proposed
transaction will not be realized, including without limitation, anticipated revenues, expenses, earnings and other financial results, and growth and expansion of the combined company’s operations, and the anticipated tax treatment of the
combination; (v) the risk that the Mergers do not qualify for the intended tax treatment; (vi) potential litigation relating to the proposed transaction that could be instituted against Passage Bio, Remix or their respective directors; (vii)
possible disruptions from the proposed transaction that could harm Passage Bio’s and/or Remix’s respective businesses; (viii) the ability of Remix to retain, attract and hire key personnel; (ix) potential adverse reactions or changes to
relationships with employees, suppliers or other parties resulting from the announcement or completion of the proposed transaction; (x) potential business uncertainty, including changes to existing business relationships, during the pendency of the
proposed transaction that could affect Passage Bio’s or Remix’s financial performance; (xi) certain restrictions during the pendency of the proposed transaction that may impact Passage Bio’s or Remix’s ability to pursue certain business
opportunities or strategic transactions; (xii) the combined company’s need for additional funding, which may not be available; (xiii) failure to identify additional product candidates and develop or commercialize marketable products; (xiv) the
early stage of the combined company’s development efforts; (xv) potential unforeseen events during clinical trials could cause delays or other adverse consequences; (xvi) risks relating to the regulatory approval process; (xvii) interim, topline
and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; (xviii) Passage Bio’s and Remix’s product candidates may cause
serious adverse side effects; (xix) inability to maintain collaborations, or the failure of these collaborations; (xx) the combined company’s reliance on third parties, including for the manufacture of materials for our research programs,
preclinical and clinical studies; (xxi) failure to obtain U.S. or international marketing approval; (xxii) ongoing regulatory obligations; effects of significant competition; (xxiii) unfavorable pricing regulations, third-party reimbursement
practices or healthcare reform initiatives; (xxiv) product liability lawsuits; (xxv) securities class action litigation; (xxvi) the impact of general economic conditions on our business and operations, including the combined company’s preclinical
studies and clinical trials; (xxvii) the possibility of system failures or security breaches; risks relating to intellectual property; (xxviii) significant costs incurred as a result of operating as a public company; (xxix) the risk that, as a
result of adjustments to the exchange ratio, Passage Bio stockholders and Remix stockholders could own more or less of the combined company than is currently anticipated, including as a result of the determination of Passage Bio’s net cash; (xxx)
risks related to the market price of Passage Bio’s common stock relative to the value implied by the exchange ratio; (xxxi) the risk that holders of the CVR may never receive any payments thereunder; (xxxii) the risk that the concurrent private
placement financing is not consummated; and (xxxiii) such other factors as are set forth in Passage Bio’s periodic public filings with the SEC, including but not limited to those described under the heading “Risk Factors” in Passage Bio’s Annual
Report on Form 10-K for the year ended December 31, 2025 and Quarterly Reports on Form 10-Q for the periods ended March 31, 2026, June 30, 2026, and September 30, 2026. Passage Bio can give no assurance that the conditions to the proposed
transaction will be satisfied. Except as required by applicable law, Passage Bio undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information,
future events or otherwise.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
PASSAGE BIO, INC.
|
| |
|
|
|
Date: November 19, 2026
|
By:
|
/s/ Kathleen Borthwick
|
| |
|
Kathleen Borthwick
|
| |
|
Chief Financial Officer
|